A novel TB vaccine; towards a strategy based on our understanding of BCG failure

The protection afforded by the currently available tuberculosis vaccine, bacillus Calmette–Guérin (BCG) is insufficient and new vaccine strategies are urgently needed. Progress in our understanding of the immunological deficits of BCG combined with novel knowledge on genetics of mycobacteria has pav...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2002-11, Vol.21 (1), p.7-14
Main Authors: Agger, E.M., Andersen, P.
Format: Article
Language:English
Subjects:
Bacterial Vaccines - chemical synthesis
Bacterial Vaccines - immunology
Bacterial Vaccines - pharmacology
Bacterial Vaccines - therapeutic use
BCG
BCG Vaccine - administration & dosage
BCG Vaccine - immunology
Biological and medical sciences
Biotechnology - methods
Biotechnology - trends
Humans
Medical sciences
Mycobacterium tuberculosis
Mycobacterium tuberculosis - drug effects
Mycobacterium tuberculosis - genetics
Mycobacterium tuberculosis - immunology
Prevention and actions
Public health. Hygiene
Public health. Hygiene-occupational medicine
Specific populations (family, woman, child, elderly...)
Technology, Pharmaceutical - methods
Technology, Pharmaceutical - trends
Tuberculosis - drug therapy
Tuberculosis - immunology
Tuberculosis - prevention & control
Vaccination
Vaccines, DNA - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The protection afforded by the currently available tuberculosis vaccine, bacillus Calmette–Guérin (BCG) is insufficient and new vaccine strategies are urgently needed. Progress in our understanding of the immunological deficits of BCG combined with novel knowledge on genetics of mycobacteria has paved the way for promising new vaccine strategies. These include recombinant modified BCG vaccines, attenuated strains of Mycobacterium tuberculosis, and various non-live candidates such as DNA and subunit vaccines. Decisive for transforming technical progress into a novel tuberculosis (TB) vaccine strategy is the recent advance in our understanding of the failure of BCG in the third world and the interaction between this vaccine and environmental mycobacteria.
ISSN:0264-410X
1873-2518
DOI:10.1016/S0264-410X(02)00447-4